Mouse striatal dopamine nerve terminals express alpha4alpha5beta2 and two stoichiometric forms of alpha4beta2*-nicotinic acetylcholine receptors.
Wild-type and alpha5 null mutant mice were used to identify nicotinic cholinergic receptors (nAChRs) that mediate alpha-conotoxin MII (alpha-CtxMII)-resistant dopamine (DA) release from striatal synaptosomes. Concentration-effect curves for ACh-stimulated release (20 s) were monophasic when wild-type synaptosomes were assayed but biphasic with synaptosomes from the alpha5 null mutant. Deleting the alpha5 gene also resulted in decreased maximal ACh-stimulated alpha-CtxMII-resistant DA release. When a shorter perfusion time (5 s) was used, biphasic curves were detected in both wild-type and alpha5 null mutants, indicative of high- and low-sensitivity (HS and LS) activity. In addition, DHbetaE-sensitive (HS) and DHbetaE-resistant (LS) components were found in both genotypes. These results indicate that alpha-CtxMII-resistant DA release is mediated by alpha4alpha5beta2, (alpha4)(2)(beta2)(3) (HS), and (alpha4)(3)(beta2)(2) (LS) nAChRs.
Grady
Sharon R
SR
Institute for Behavioral Genetics, University of Colorado, Boulder, CO, USA.
Salminen
Outi
O
McIntosh
J Michael
JM
Marks
Michael J
MJ
Collins
Allan C
AC
D000109:Acetylcholine / Q000378:metabolism / Q000494:pharmacology; D000818:Animals; D020916:Conotoxins / Q000494:pharmacology; D003342:Corpus Striatum / Q000737:chemistry / Q000378:metabolism*; D004298:Dopamine / Q000378:metabolism*; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D009154:Mutation / Q000235:genetics; D018733:Nicotinic Antagonists / Q000494:pharmacology; D017729:Presynaptic Terminals / Q000737:chemistry / Q000378:metabolism*; D021122:Protein Subunits / Q000737:chemistry / Q000235:genetics / Q000378:metabolism; D011978:Receptors, Nicotinic / Q000737:chemistry / Q000235:genetics / Q000378:metabolism*; D013574:Synaptosomes
D000109:Acetylcholine; D020916:Conotoxins; D004298:Dopamine; D018733:Nicotinic Antagonists; D021122:Protein Subunits; D011978:Receptors, Nicotinic; C098872:alpha-conotoxin MII; C403531:nicotinic receptor alpha4beta2; C523972:CHRNA5 protein, mouse
Mol Pharmacol. 2009 Apr;75(4):918-26
19139153
Mol Pharmacol. 2007 Jun;71(6):1563-71
17341654
Mol Pharmacol. 2003 Feb;63(2):332-41
12527804
Neuropharmacology. 2005 Apr;48(5):696-705
15814104
J Neurochem. 2001 Jan;76(1):258-68
11145999
Mol Pharmacol. 1998 Dec;54(6):1124-31
9855643
Neuropharmacology. 2007 Sep;53(3):390-405
17631923
Neuropharmacology. 2000 Oct;39(13):2632-45
11044733
J Biol Chem. 1996 Mar 29;271(13):7522-8
8631783
Mol Pharmacol. 2008 Jul;74(1):132-43
18381563
Mol Pharmacol. 2003 May;63(5):1059-66
12695534
J Neurochem. 1992 Sep;59(3):848-56
1494911
J Neurosci. 2003 Aug 27;23(21):7820-9
12944511
J Pharmacol Exp Ther. 1998 Jul;286(1):311-20
9655874
Mol Pharmacol. 2006 Aug;70(2):755-68
16720757
Mol Pharmacol. 2004 Jun;65(6):1526-35
15155845
J Neurochem. 2007 Oct;103(1):204-15
17573823
Neuroscience. 2004;124(4):817-22
15026122
J Pharmacol Exp Ther. 1999 May;289(2):1090-103
10215692
J Neurosci. 1997 Jul 15;17(14):5263-70
9204910
Mol Pharmacol. 2008 Jun;73(6):1796-807
18337473